Please login to the form below
cost
This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.
NHS England sees off AbbVie's Hep C legal challenge
NHS England says it will save £300m by negotiating deals with five manufacturers on low cost versions of adalimumab, which has been the single biggest drug cost for the health service
Latest news
-
NICE gives Lilly’s Verzenios chance to compete with rivals
Lilly got the green light after improving its price offering via a revised patient access scheme, and NICE says it is now cost effective relative to the other treatments in the
-
J&J’s Erleada cleared for early prostate cancer in Europe
Zytiga lost a patent infringement appeal last year however, so the later-stage market is poised for the entry of low-cost generics which could also put J&J’s drug
-
Pfizer takeover rumour ignites Amarin shares
The results rivalled the efficacy seen in cardiovascular outcomes trials for Amgen’s PCSK9 antibody Repatha (evolocumab), and Vascepa’s relatively low cost and lack of side effects means it could
-
Blackwood returns as new life sciences minister
cost, as this would see the UK sector cut adrift in trade and regulatory terms from the rest of Europe.
-
NICE rejects Novartis migraine treatment Aimovig
Ahmad adds: “NICE does not consider impact of diseases on broader society when evaluating the cost-effectiveness of medicines. ... As migraine predominantly affects people of working age, it costs the UK economy £8.8 billion per year in lost
More from news
Approximately 9 fully matching, plus 2,596 partially matching documents found.
Latest Intelligence
-
The UK’s new five-year pricing agreement
NICE basic cost-effectiveness threshold to be retained at the current range (£20, 000 £30, 000 per quality-adjusted life year) for the duration of the voluntary scheme. ... the government dictates, or forcing all companies into a statutory scheme, is
-
Relearning launch: Four key dynamics for pharma launches in 2019
Regulators, payers and large, organised customers expect to see an evidence package that includes impact on cost of illness, burden of illness, quality of life and impact on caretakers. ... Despite these relatively new levers of cost control, early
-
Combined immunotherapies – potential and pitfalls
This contrasts with the approved ipilimumab-nivolumab combination therapy, which costs $256, 000 a year, according to the researchers.
-
Diagnosed Anywhere
Around the globe, the cost and waiting game to see a doctor will drive growth and utilisation of alternate diagnostic tools, at a moment when innovators large and small are uncovering
-
New models of NHS care – new models of pharma response?
CAR-T therapies are cost-effective for these patients, but the service redesign required is just as big a challenge.”. ... James Roach. Many of England’s acute providers are ‘technically bankrupt’, he says, requiring an accelerated move to more
More from intelligence
Approximately 2 fully matching, plus 410 partially matching documents found.
Latest appointments
-
Merck appoints new chief information officer
He has a proven track record in successfully managing large-scale IT transformation initiatives, as well as building cost-effective international IT organisations.”.
-
Peter Kelly named managing director of Accord Healthcare UK
We remain committed to R&D and bringing cost competitive new products to market at the earliest opportunity.
-
IFPMA appoints Fumie Griego as assistant director general
and background in global affairs, including intellectual property protection, pricing, costs, value issues and health diplomacy.
-
Sandoz UK promotes Tim de Gavre to country head
As a market, the UK has one of the highest levels of generic use of any global market, and the NHS is also under severe cost pressures. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs,
-
EY appoints global life sciences industry leader
New solutions will be required to meet the global challenges of sustainability of healthcare systems, aging populations, chronic disease and increasing cost pressures.
More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest from PMHub
-
New opportunities in emerging markets
aggressive cost containment measures).
-
Clinical Trials Market Global Industry Analysis, size, share and Forecast 2018-2028
Lesser insurance coverage and growing medical expenses due to increasing presence of private hospitals is leading to rapidly increasing need for clinical trials for accessing free-of-cost high-quality healthcare. ... Reduced labor cost for the clinical
-
Real-Time E-Healthcare System Market to Expand at a Healthy Pace in the Coming Years
Request Sample Report @ . Real-Time E-Healthcare System Market: Drivers &Restraints . Technological advancement, increasing disposable income, increase use of online services, increase use of mobile devices, increased health cost and
-
Medical Device Technologies Market Dynamics, Segments and Supply Demand 2015 - 2025
The new technologies have reduced the recovery time and cost of instrument for the patient. ... Strict regulations have improved the competitiveness of the companies with respect to cost and quality.
-
Cardiovascular Enterprise Viewer Market In-Depth Market Research and Major Growth Report by 2025
However, lack of required skills and IT domain expertise, maintaining IT infrastructure and services, and huge cost of cardiovascular enterprise viewer act as major barrier for this market.
More from PMHub
Approximately 3 fully matching, plus 337 partially matching documents found.
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Medical Writer
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
-
Senior Medical Writer
-
Salary TBC
-
Account Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
Conversis
Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
